Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Legnano – page 224

2 907 clinical trials in Legnano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Legnano at a glance
2 907
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 907 trials in Legnano

Open in trial search

Transitional cell cancer of the renal pelvis and ureter

Not recruiting

Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Gilead Sciences Inc.

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia

Not recruiting

Study of Venetoclax and Azacitidine for Patients with Acute Myeloid Leukemia After Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Abbvie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study Comparing Venetoclax and Dexamethasone with Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:Abbvie Deutschland GmbH & Co. KG

Study on Andexanet Alfa for Patients on Factor Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban) Needing Urgent Surgery to Reduce Bleeding Risk

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aminocaproic Acid
  • Sponsor:Astrazeneca AB

Non-small cell lung cancer+1

Not recruiting

Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer

Not recruiting

Study to Test Pembrolizumab, MK-4830, and MK-0482 in Patients with Advanced Non-Small Cell Lung Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MK-4830
  • Sponsor:Merck Sharp & Dohme LLC

Chronic hepatitis B+1

Not recruiting

Study of Bepirovirsen for Patients with Chronic Hepatitis B on Nucleos(t)ide Analogue Treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Not recruiting

Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:DCC-3116
  • Sponsor:Deciphera Pharmaceuticals Inc.

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Non-small cell lung cancer

Not recruiting

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Malignant melanoma

Not recruiting

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Legnano

What the registry says about research in the country

01 Hematologic Oncology

Extensive research focusing on Multiple Myeloma treatments, including innovative therapies for relapsed and refractory cases. Studies evaluating new drug combinations and treatment approaches for better patient outcomes.

  • Melflufen therapy for elderly patients
  • Elranatamab monotherapy trials
  • Novel combination treatments for RRMM

Multiple ongoing trials testing various therapeutic combinations to improve survival rates.

02 Solid Tumors

Groundbreaking studies in lung cancer and breast cancer treatment, investigating novel immunotherapy combinations and targeted therapies.

  • Advanced NSCLC immunotherapy trials
  • HER2-positive breast cancer treatments
  • Colorectal cancer targeted therapies

Focus on personalized treatment approaches and biomarker-driven therapies.

03 Chronic Conditions

Innovative research in chronic kidney disease and HIV management, exploring new treatment strategies and medication combinations.

  • Non-diabetic kidney disease treatments
  • HIV antiretroviral therapy optimization
  • Ulcerative colitis interventions

Studies aimed at improving long-term patient outcomes and quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.